US Patent 8,546,436: What Is Claimed, Where It Sits in the Landscape, and How Other Patents Likely Interlock
US Patent 8,546,436 covers crystalline polymorphs of a single small-molecule API and claims (i) polymorph identity by X-ray powder diffraction (XRPD) peak sets, (ii) polymorph preparation conditions, and (iii) solid-state pharmaceutical compositions containing the polymorphs.
The asserted coverage is tight on the polymorphs’ XRPD fingerprints and looser on formulation, because formulation claims are functional (“effective amount” plus “excipients/carriers”) while the API form claims are explicitly defined by 2θ peak locations.
What exactly does the patent claim? (Claim-by-claim scope)
Core API definition: polymorphs by XRPD peak positions
Claims 1 to 4 lock down specific crystalline forms using XRPD peak lists:
| Claim |
Crystalline form scope |
XRPD characterization (2θ, ±0.1°) |
| 1 |
Polymorph of the named acetic acid |
Peaks at 10.32, 18.84, 20.75 |
| 2 |
Another polymorph of the same acetic acid |
Peaks at 10.46, 18.76, 19.83 |
| 3 |
Dependent refinement of claim 2 |
Claim 2 polymorph plus at least one further peak at 18.21 or 23.08 |
| 4 |
Dependent refinement of claim 2 |
XRPD pattern “substantially the same as” the pattern in FIG. 5 |
Claim 4 expands risk slightly beyond the explicit numeric list in claim 2 because “substantially the same” can be argued to cover small peak shifts, additional peaks, and intensity variations, depending on how the figure is interpreted in litigation and claim construction. The patent still anchors validity and scope to the XRPD profile, but it is not limited to one three-peak set.
Manufacturing scope: crystallization and isolation routes
Claims 5, 7 to 10 cover preparation of the polymorphs, with route-specific limitations.
| Claim |
Coverage type |
Key limitations |
| 5 |
Preparation method of claim 2 polymorph |
Crystallize the API from water + ethyl acetate |
| 7 |
Process (detailed workup) yielding claim 2 polymorph |
Dissolve sodium salt in water → add mineral acid → add ethyl acetate → separate organic layer → precipitate polymorph from organic layer; polymorph must match peaks 10.46, 18.76, 19.83 |
| 8 |
Dependent process options |
Mineral acid = hydrobromic acid; acid added at ~1.05 equivalents; reduce organic layer volume; cool organic layer; filtration/washing; plus optional further peak (18.21 or 23.08) |
| 9 |
Alternative two-phase conversion route |
Contact sodium salt with aqueous hydrogen bromide and organic solvent to form aqueous and organic phases; isolate organic phase; crystallize API from organic phase |
| 10 |
Alternative crystallization variant |
Crystallize from water + ethyl acetate (note: claim text references a slightly different spelling variant in the substituent line, but scope still targets the same named acetic acid scaffold) |
Practical read-through for freedom-to-operate (FTO):
- Any process that forms the polymorph and can prove the XRPD matches the claimed pattern is within scope even if the process differs, but only if the claim is the one that is being asserted.
- Conversely, if a competitor uses a different solvent system or different acid/stoichiometry such that the resulting crystals do not match the claimed XRPD signature, process claims 7-10 narrow away sharply.
Formulation scope
Claims 6 and 11 claim solid pharmaceutical compositions that use the polymorph(s) as active ingredient.
| Claim |
Formulation scope |
What is required |
| 6 |
Solid pharmaceutical composition |
“Effective amount” of the API where the API comprises the claim 2 polymorph + at least one excipient/carrier |
| 11 |
Solid composition mixing forms |
Composition includes claim 1 form and claim 2 form each as active ingredients + excipient/carrier |
Implication: formulation coverage is broad in the excipient sense but strict in the polymorph content. If a product uses only the claim 1 form or only the claim 2 form, claim 11 is avoided; if it uses the claim 2 polymorph, claim 6 is implicated.
What is the binding “scope engine” of the claims? (XRPD peak-set control)
The claim set is built around a specific legal concept: crystal identity by a technical analytical method.
Claim 1 polymorph fingerprint
- 10.32°, 18.84°, 20.75° (±0.1°)
Claim 2 polymorph fingerprint
- 10.46°, 18.76°, 19.83° (±0.1°)
- Claim 3 requires at least one additional peak at 18.21° or 23.08° (±0.1°)
- Claim 4 allows “substantially the same” as FIG. 5
Design consequence for patent landscape and technical differentiation:
A competitor can attempt to create a form that stays outside the exact three-peak alignment. But claim 3 and claim 4 create friction:
- claim 3 captures some “plus-peak” variants, and
- claim 4 captures figure-matched profiles.
So the “escape” strategy cannot rely only on swapping one minor peak; it has to avoid the core claim 2 peak set or the substantially-same figure profile, depending on how infringement is tried.
Where does the patent sit in the typical US crystalline polymorph ecosystem? (Landscape positioning)
With only the claims text provided, the landscape analysis must be done at the level of claim architecture and usual interlocking patent types around polymorph families. US 8,546,436 is structurally consistent with a portfolio lane that is commonly observed in crystalline API programs:
1) Early scaffold protection (not in this patent’s claims)
This patent does not claim synthesis of the scaffold per se; it claims crystal forms and form-specific processes.
So the molecule itself (the substituted triazole-thio-acetic acid core) is likely covered by:
- a broader composition-of-matter patent, or
- earlier process or method patents.
US 8,546,436 is best viewed as a later-stage patent that:
- carves out specific solid-state forms of the same active ingredient,
- and blocks generic manufacturers by locking the polymorph and the route-to-polymorph.
2) “Polymorph-by-XRPD” patents
US 8,546,436 is exactly this. It uses a tight XRPD claim format:
- three-peak anchor lists,
- optional additional peaks,
- and a figure-based “substantially the same” alternative.
3) Process-dependent polymorph formation
Claims 7 to 10 show the same: crystalline form obtained through defined acid/solvent/phase separation and crystallization.
That is a classic posture for blocking:
- “generic API” producers who buy an intermediate but crystalize in-house, and
- contract manufacturers who choose a crystallization route that can generate the exact polymorph.
4) Solid dosage-form blockade
Claims 6 and 11 allow enforcement downstream at:
- the intermediate isolated API stage (if direct infringement is found via the polymorph),
- and the finished solid dosage-form stage if the product’s active corresponds to the claimed form.
What are the infringement pressure points for competitors?
If a competitor markets the claim 2 polymorph
- Claim 6 is directly triggered if the marketed solid composition uses the claim 2 polymorph as active ingredient.
- Claim 7/8/9/10 become relevant if a supplier’s process produces the polymorph and the accused process can be mapped to the route limitations.
If a competitor uses a mixed-form product
- Claim 11 is a stronger target: it requires both claim 1 form and claim 2 form in the same solid pharmaceutical composition.
So a competitor formulating with only one form can avoid claim 11, but may still face claim 6 (if claim 2 is used).
If a competitor claims a different polymorph
- The patent’s core defenses and offenses are pinned to XRPD peaks.
- The landscape risk concentrates on whether the competitor’s “different polymorph” actually has:
- the claim 2 peak positions (within ±0.1°), or
- a pattern “substantially the same” to FIG. 5.
What does the patent likely enable for enforcement strategy?
The claim set supports three enforcement angles:
-
Direct infringement of product using claim 2 polymorph
- Use XRPD testing of incoming API lots and finished dosage forms to show matching peaks.
-
Process infringement against crystallization routes
- Map crystallization/precipitation steps against claim 7/8/9/10, then test resulting crystals’ XRPD signature.
-
Form-combination enforcement
- If a competitor uses a formulation that intentionally mixes forms, claim 11 provides a crisp target.
Key claim-to-process mapping (what to look for in production records)
For a competitor’s crystallization dossier or batch record, the most probative elements under claims 7-10 are:
- Starting material: sodium 2-(...)acetate
- Acid type: mineral acid, specifically hydrobromic acid under claim 8
- Approximate equivalent: ~1.05 equivalents under claim 8
- Solvent system:
- ethyl acetate as the organic layer in claim 7/5/10
- aqueous hydrogen bromide + organic solvent phase separation in claim 9
- Isolation:
- separating organic layer
- precipitating crystals from organic layer
- filtration and washing
- optional volume reduction and cooling
Those steps create a concrete factual checklist for infringement analysis.
What would a “blocking” impact look like across the landscape?
Even without a full citation list of related patents, US 8,546,436 implies a classic polymorph-blocking pattern:
- Generic manufacturers must control crystallization conditions tightly to avoid producing the exact polymorphs defined by the peak lists.
- Commercial suppliers who provide an API to generics face risk if they can’t prove the polymorph identity is outside claim 1/2.
- Contract development and manufacturing organizations (CDMOs) become potential enforcement targets if their standard crystallization recipes align with claim 7/8/9/10.
Key Takeaways
- US 8,546,436 is an XRPD-defined polymorph patent for one API, with two main crystalline forms (claims 1 and 2) anchored to specific 2θ peak sets.
- Claim 2 drives the largest downstream risk: it is used in the formulation claim (claim 6) and process claims (7-10).
- Process claims are route-controlled (sodium salt hydrolysis/acidification/ethyl acetate phase separation, hydrobromic acid variants, crystallization conditions) but the ultimate gatekeeper is still whether the resulting crystals match the claimed XRPD pattern.
- Claim 11 targets mixed polymorph compositions (claim 1 + claim 2 together).
- The landscape posture is consistent with a late-stage solid-state life-cycle strategy: blockade solid products and block generic crystallization that yields the same polymorph.
FAQs
1) Does the patent claim the molecular structure or only the crystalline forms?
It claims crystalline polymorphic forms of the named acetic acid by XRPD peak positions, plus processes to prepare those polymorphs and solid pharmaceutical compositions using the polymorph(s) as active ingredient.
2) What XRPD peaks define the primary polymorph at issue in formulation claims?
Claim 2 is defined by 10.46, 18.76, and 19.83° 2θ (±0.1°), with dependent claim 3 adding a further peak at 18.21 or 23.08° and claim 4 allowing a FIG. 5 “substantially the same” XRPD pattern.
3) Can a competitor avoid infringement by using a different solvent system?
Only if the different process yields crystals that do not match the claimed XRPD signatures. The process claims are solvent and workup limited, but the polymorph claims hinge on XRPD identity.
4) Is there a claim that covers using both polymorphs in one product?
Yes. Claim 11 requires the solid pharmaceutical composition to include form 1 (claim 1) and form 2 (claim 2) as active ingredients together.
5) Which claims are most relevant for generic solid dosage-form risk?
Claim 6 for compositions using the claim 2 polymorph, and claim 11 for compositions that include both claim 1 and claim 2 polymorphs.
References
[1] Provided in prompt: Claims for US Drug Patent 8,546,436 (claim text and XRPD peak data).
